Trial Profile
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Haemangioendothelioma; Haemangiosarcoma; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Squamous cell cancer; Uveal melanoma
- Focus Adverse reactions
- 28 Sep 2023 Planned End Date changed from 31 Oct 2023 to 30 Jun 2025.
- 28 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 30 Jun 2024.
- 26 Jun 2023 Planned End Date changed from 1 Jun 2025 to 31 Oct 2023.